. Sourya Acharya; . Sunil Kumar; . Ruchita Kabra; . Mansi Patel; . Neha Phate; . Dhruv Talwar; . Varun Daiya
Volume 13, Issue 1 , January 2023, , Pages 1-5
Abstract
BACKGROUND: The angiotensin‑converting enzyme 2 (ACE2) receptor, a membrane receptorpresent in the respiratory system, the gastrointestinal tracts, the heart, and the kidney is the ...
Read More
BACKGROUND: The angiotensin‑converting enzyme 2 (ACE2) receptor, a membrane receptorpresent in the respiratory system, the gastrointestinal tracts, the heart, and the kidney is the entrypoint for SARS‑CoV‑2 to enter human cells. Concerns were raised about the influence of usingantihypertensive drugs like angiotensin‑converting enzyme inhibitors (ACEIs) or angiotensin receptorblockers (ARBs) in individuals with COVID‑19 due to its tight relationship with the ACE2 receptor. Theaim of this study was to investigate the impact of being on an Angiotensin Receptor Blockers (ARB)on mortality in patients consecutively diagnosed with COVID‑19.MATERIAL AND METHODS: This is the retrospective observational study done in all patientsconsecutively diagnosed with COVID‑19 from January 2021 to June 2021. All related patientinformation and clinical data was retrieved from the hospitals electronic medical record system.RESULTS: In this study, out of 500 patients, 51 died, having mean age of 66.92 ± 10.85 years.144 (28.8%) patients were on angiotensin receptor blockers as antihypertensive treatment,142 (28.4%) having other antihypertensive and 214 (42.8%) were not on any treatment. Out of 51Death 7 (4.9) patients were on ARBs, 15 ± 10.6 were on other medication [OR 2.31 (0.94–6.22,P = 0.077) univariable; OR 2.57 (1.00–7.23, P = 0.058) multivariable] and 29 ± 13.6 had no treatmentat all [OR 3.07 (1.38–7.80, P = 0.010) univariable; OR 3.36 (1.41–9.08, P = 0.010) multivariable].CONCLUSION: Use of ARB medications for the hypertensive patients who acquire COVID‑19infection has shown protective effects of such medications on COVID‑19 disease severity in theterm of mortality and the mortality rate among hypertensive patients on COVID‑19 with ARBs/ACEinhibitors showed significant differences as compared to other antihypertensives.
